Bioprofarma Bagó is pleased to introduce IMPILO® bexarotene, for its Hematology Line, replacing the historical TARGRETIN® bexarotene.
Based on its experience to maintain the same quality standards that characterize the company, IMPILO® bexarotene was developed locally, which will benefit supply, helping patients access to continue their treatments.
IMPILO® bexarotene is approved by ANMAT for the treatment of cutaneous manifestations of patients in advanced stages of cutaneous T-cell lymphoma (CTCL) in adult patients resistant to, at least, one previous treatment.
IMPILO® bexarotene is supplied in a single presentation containing 100 75 mg soft capsules.
Now, the treatment of CTCL is with IMPILO®
